Eplerenone - Cardiovascular protection

被引：117

作者：

Brown, NJ

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA

来源：

CIRCULATION | 2003年 / 107卷 / 19期

关键词：

aldosterone; receptors; cardiovascular disease; hypertension; pharmacology;

D O I：

10.1161/01.CIR.0000071081.35693.9A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Data from animal studies and clinical trials indicate that aldosterone causes cardiovascular and renal injury through mineralocorticoid receptor-dependent mechanisms. However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific aldosterone receptor antagonist, spironolactone, have limited its usefulness in the treatment of hypertension. This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity.

引用

收藏

页码：2512 / 2518

页数：7

相关论文

共 71 条

[51] Aldosterone: A mediator of myocardial necrosis and renal arteriopathy [J].

Rocha, R ;

Stier, CT ;

Kifor, I ;

Ochoa-Maya, MR ;

Rennke, HG ;

Williams, GH ;

Adler, GK .

ENDOCRINOLOGY, 2000, 141 (10) :3871-3878

[52] Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats [J].

Rocha, R ;

Chander, PN ;

Khanna, K ;

Zuckerman, A ;

Stier, CT .

HYPERTENSION, 1998, 31 (01) :451-458

[53] Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart [J].

Rocha, R ;

Martin-Berger, CL ;

Yang, PC ;

Scherrer, R ;

Delyani, J ;

McMahon, E .

ENDOCRINOLOGY, 2002, 143 (12) :4828-4836

[54]

SADEE W, 1973, J PHARMACOL EXP THER, V185, P686

[55] Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis [J].

Sato, A ;

Funder, JW ;

Saruta, T .

AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (09) :867-873

[56] Myocardial production of aldosterone and corticosterone in the rat - Physiological regulation [J].

Silvestre, JS ;

Robert, V ;

Heymes, C ;

Aupetit-Faisant, B ;

Mouas, C ;

Moalic, JM ;

Swynghedauw, B ;

Delcayre, C .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) :4883-4891

[57]

Simpson SA, 1953, MEM SOC ENDOCR, V2, P9

[58] RISE IN PLASMA-CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN(II)SUPPRESSION [J].

STAESSEN, J ;

LIJNEN, P ;

FAGARD, R ;

VERSCHUEREN, LJ ;

AMERY, A .

JOURNAL OF ENDOCRINOLOGY, 1981, 91 (03) :457-465

[59] HORMONES REGULATING CARDIOVASCULAR FUNCTION IN PATIENTS WITH SEVERE CONGESTIVE-HEART-FAILURE AND THEIR RELATION TO MORTALITY [J].

SWEDBERG, K ;

ENEROTH, P ;

KJEKSHUS, J ;

WILHELMSEN, L .

CIRCULATION, 1990, 82 (05) :1730-1736

[60] VASODILATION TO ACETYLCHOLINE IN PRIMARY AND SECONDARY FORMS OF HUMAN HYPERTENSION [J].

TADDEI, S ;

VIRDIS, A ;

MATTEI, P ;

SALVETTI, A .

HYPERTENSION, 1993, 21 (06) :929-933

← 1 2 3 4 5 6 7 8 →